Safety and efficacy anticoagulation in extracorporeal hemodialysis by simultaneous administration of low-dose prostacyclin and low molecular weight heparin

Minerva Medica

Volumn 89, Issue 11-12, 1998, Pages 405-409

  Camici, M ^a   Giordani, R ^a   Morelli, E ^a   Meriggioli, M ^a   Balestri, P L ^a   Barsotti, G ^a   Sagripanti, A ^a  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

Anticoagulants therapeutic use; Epoprostenol; Hemodialysis; Heparin, low molecular weight

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN III; CREATININE; FIBRINOGEN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PHOSPHATE; PROSTACYCLIN; URIC ACID;

ADULT; ANTICOAGULATION; ARTERIAL PRESSURE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FIBRINOGEN BLOOD LEVEL; HEART RATE; HEMODIALYSIS; HEMODYNAMIC PARAMETERS; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; MALE; MOLECULAR WEIGHT; PARTIAL THROMBOPLASTIN TIME; PHOSPHATE BLOOD LEVEL; UREA BLOOD LEVEL; URIC ACID BLOOD LEVEL;

ADULT; ANTICOAGULANTS; EPOPROSTENOL; FEMALE; HEMODIAFILTRATION; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS;

EID: 0032455880     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Grootendorst AF, van Bommel EFH The role of hemofiltration in the critically-ill intensive care unit patient: present and future Blood Purification 1993;11:209-23.
2. Stefanidis I, Hagel J, Maunn N. Influence of coagulation parameter on filter running time during continous venovenous hemofiltration. Contr Nephrol. Basel: Karger 1995;116:145-9.
3. Bastien O, French P, Paulus S, Filley S, Berruyer M, Dechavenne M, Estanove S. Antithrombin III deficiency during continous venovenous hemodialysis. Contr Nephrol. Basel: Karger 1995;116:154-8
4. Brandt JT, Douglas A, Triplett DA. Laboratory monitoring of heparin. Effect of reagents and instruments on the activated partial thromboplastin time. Am J Clin Pathol 1981;76:530-7.
5. Remuzzi G, Benigni A, Dodesini P, Schieppati A, Gotti E, Livio M et al. Platelet function in patients on maintenance hemodialysis: depremsed or enhanced? Clin Nephrol 1982;17(2):60-3.
6. Kazuomi K, Takefumi M, Tsutomu Y, Kazukiyo N, Chikako S, Miyako M Factor VII hyperactivity in chronic dialysis patients Thromb Res 1992;67:105-13.
7. Maurin N. The in vitro bleeding time while using a stable prostacyclin analogue during hemodialysis. Int J Art Org 1988;11:243-8.
8. Camici M, Evangelisti L. Prostacyclin and heparin during hemodialysis: comparative effects. Life Support System 1986;4:205-9.
9. Ylikorkola O, Huttunen K, Jarvi J, Viinikka L. Prostacyclin and thromboxane in chronic uremia. Effect of hemodialysis. Clin Nephrol 1982;18(2):83-7.
10. Kaji T, Yamamoto C, Sakamoto M. Low molecular weight heparin enhances prostacyclin production by cultured human endothelial cells. Chem Pharm Bull 1991;39(12):3368-9.
11. Dubrow A, Flanembaum W, Mittman N, Hall J, Zinn J. Safety and efficiency of epoprostenol (PGI) versus heparin (H) in hemodialysis (Hd) Trans Am Soc Art Int Org 1984;30:52-4.
12. Limbs JL, Stephen D, Welsch M, Barthelmebs M, Eisenmann B Pharmacologie clinique de la prostacycline et de ses analogues stables. Therapie 1991;46:211-6.
13. Fukushima M. Biological activities and mechanisms of action of PGI2 and related compounds: an update. Prost Leuk Ess Fatty Acids 1992;47:1-12.
14. Choay J. Structure and activity of hepann and its fragments: an overview. Semin Thromb Hemost 1989;14(4):359-64.
15. Boneu B. Low molecular weight heparin therapy: is monitoring needed? Thromb Haemost 1994;72(39):330-4.
16. Breddin KH. Low molecular weight heparin and bleeding. Semin Thromb Hemost 1982;15(4):401-4.
17. Westwick J, Scully MF, Poll C, Kakkar VV. Comparison of the effects of low molecular weight heparin and unfractionated heparin on activation of human platelet in vitro. Thromb Res 1986;42(4):435.
18. Goudable S, Saivin S, Houin G, Sie P, Boneu B, Touthat H et al Pharmacokinetics of a low molecular weight heparin (Fraxiparine) in various stages of chronic renal failue. Nephron 1991;59:543-5.
19. Ljungberg B, Blomback M, Johnsson H, Lins LE. A single dose of a low molecular weight heparin fragment for anticoagulation during hemodialysis. Clin Nephrol 1987;27:31-5.
20. Schrader J, Stibbe W, Armstrong VW, Kandt M, Muche R, Kostering H et al Comparison of low molecular weight heparin to standard heparin in hemodialysis/hemofiltration Kidney Int 1988;33:980-6.
21. Lindhout TH, Pieters J, Beguin S, Hemker C. The mode of action of CY216 on thrombin generation in plasma. In: Fraxiparine, First International Symposium, Breddin K, Fareed J, Samama M, editors. New York: Schattauer, Stuttgart, 1989:23.
22. Verstraete M. Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins. Drugs 1990;40(4):498-530.